Main description:

The Advances in Pharmacology series presents a variety of chapters from the best authors in the field.

Contents:

Part I - Neurobiology of ketamine effects

Effects of ketamine and other rapidly acting antidepressants on hippocampal excitatory and inhibitory transmission
Allie J. Widman and Lori L. McMahon

Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition
Bernhard Luscher, Mengyang Feng and Sarah J. Jefferson

The role of eEF2 kinase in the rapid antidepressant actions of ketamine
Kanzo Suzuki and Lisa M. Monteggia

Part II - The rapid therapeutic effects of ketamine

Clinical overview of NMDA-R antagonists and clinical practice
Pasha A. Davoudian and Samuel T. Wilkinson

Ketamine for depression clinical issues
Syed Z. Iqbal and Sanjay J. Mathew

Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence
Lynnette A. Averill, Samar Fouda, James W. Murrough and Chadi G. Abdallah

Neurobiological biomarkers of response to ketamine
Bashkim Kadriu, Elizabeth D. Ballard, Ioline D. Henter, Stephen Murata, Nimesha Gerlus and Carlos A. Zarate Jr

Relapse prevention in treatment resistant major depressive disorder with rapid-acting antidepressants
Jaskaran B. Singh, Maggie Fedgchin, Ella J. Daly and Wayne C. Drevets

The emergence of ketamine as a novel treatment for posttraumatic stress disorder
Adriana Feder, Sarah B. Rutter, Daniela Schille and Dennis S. Charney

Part III - Novel rapid-acting antidepressant mechanisms related to ketamine

mGlu2/3 receptor as a novel target for rapid acting antidepressants
Shigeyuki Chaki

Involvement of muscarinic receptor mechanisms in antidepressant drug action
Jeffrey M. Witkin, Jodi L. Smith, Lalit K. Golani, Emily A. Brooks and Anna E. Martin

The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions

Wayne C. Drevets, Anindya Bhattacharya and Maura L. Furey